Partnership Between Continuity Biosciences and Breakthrough T1D for NICHE® Cell Therapy Platform Advancement Continuity Biosciences and Breakthrough T1D have partnered to advance the NICHE® cell therapy platform, aiming for initial human studies in type 1 diabetes.

Partnership Between Continuity Biosciences and Breakthrough T1D for NICHE® Cell Therapy Platform Advancement #USA #Cary,_North_Carolina #Breakthrough_T1D #Continuity_Biosciences #NICHE®

Continuity Biosciences and Breakthrough T1D Join Forces to Propel NICHE® Cell Therapy Platform Forward Continuity Biosciences has partnered with Breakthrough T1D to advance the NICHE® cell therapy platform into its first human trial, enhancing treatment for Type 1 Diabetes.

Continuity Biosciences and Breakthrough T1D Join Forces to Propel NICHE® Cell Therapy Platform Forward #USA #Cary,_NC #Breakthrough_T1D #Continuity_Biosciences #NICHE®

Continuity Biosciences Welcomes Josephine Torrente and Joseph DeSimone to Its Board of Directors Continuity Biosciences has announced the appointment of Josephine Torrente and Dr. Joseph DeSimone to its board, marking a significant step forward.

Continuity Biosciences Welcomes Josephine Torrente and Joseph DeSimone to Its Board of Directors #USA #Bradenton #Continuity_Biosciences #Josephine_Torrente #Joseph_DeSimone

Continuity Biosciences Names New Board Members to Enhance Drug Delivery Innovations Continuity Biosciences has appointed Josephine Torrente and Joseph DeSimone, PhD, to its board, enhancing the company's drug delivery technology efforts with their expertise.

Continuity Biosciences Names New Board Members to Enhance Drug Delivery Innovations #USA #Bradenton,_Florida #Continuity_Biosciences #Josephine_Torrente #Joseph_DeSimone

Continuity Biosciences Strengthens Board with New Additions to Fuel Innovation in Drug Delivery Continuity Biosciences has appointed Josephine Torrente and Dr. Joseph DeSimone to its Board, enhancing its expertise in drug delivery and regulatory strategy.

Continuity Biosciences Strengthens Board with New Additions to Fuel Innovation in Drug Delivery #USA #Bradenton #Continuity_Biosciences #Josephine_Torrente #Joseph_DeSimone

Continuity Biosciences Acquires Focal Medical to Enhance Targeted Drug Delivery for Pancreatic Cancer Continuity Biosciences has completed the acquisition of Focal Medical, a key step in advancing targeted therapies for inoperable solid tumors, notably pancreatic cancer.

Continuity Biosciences Acquires Focal Medical to Enhance Targeted Drug Delivery for Pancreatic Cancer #USA #pancreatic_cancer #Bradenton #Continuity_Biosciences #Focal_Medical

Continuity Biosciences Acquires Focal Medical to Enhance Pancreatic Cancer Treatment Continuity Biosciences has secured Focal Medical, enhancing their ability to deliver targeted therapies for pancreatic cancer through innovative drug delivery methods.

Continuity Biosciences Acquires Focal Medical to Enhance Pancreatic Cancer Treatment #USA #pancreatic_cancer #Bradenton #Continuity_Biosciences #Focal_Medical

Continuity Biosciences Acquires Focal Medical to Enhance Targeted Drug Delivery Innovations Continuity Biosciences has recently acquired Focal Medical, aiming to advance targeted drug delivery technologies. This strategic move focuses on better treatment options for pancreatic cancer patients.

Continuity Biosciences Acquires Focal Medical to Enhance Targeted Drug Delivery Innovations #USA #pancreatic_cancer #Bradenton #Continuity_Biosciences #Focal_Medical

Continuity Biosciences Executes Strategic Acquisition of Focal Medical to Enhance Targeted Drug Delivery for Pancreatic Cancer Continuity Biosciences has successfully acquired Focal Medical, aiming to revolutionize targeted drug delivery in pancreatic cancer treatment with innovative iontophoresis technology.

Continuity Biosciences Executes Strategic Acquisition of Focal Medical to Enhance Targeted Drug Delivery for Pancreatic Cancer #USA #pancreatic_cancer #Bradenton #Continuity_Biosciences #Focal_Medical

Continuity Biosciences Expands into Aesthetic Drug Delivery with PinPrint Investment Continuity Biosciences makes a strategic investment in PinPrint, enhancing its capabilities in delivering aesthetic and cosmetic treatments through innovative microneedle technology.

Continuity Biosciences Expands into Aesthetic Drug Delivery with PinPrint Investment #USA #Bradenton #Microneedle_Technology #Continuity_Biosciences #PinPrint

Continuity Biosciences Enhances its Portfolio with Investment in PinPrint for Aesthetic Drug Delivery Continuity Biosciences strategically invests in PinPrint to broaden its reach in the aesthetic and cosmetic drug delivery sector, leveraging revolutionary 3D-printed microneedle technology.

Continuity Biosciences Enhances its Portfolio with Investment in PinPrint for Aesthetic Drug Delivery #USA #3D_Printing #Bradenton #Continuity_Biosciences #PinPrint